Research ArticleCardiology
Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04
Zohreh Varasteh, Sarajo Mohanta, Stephanie Robu, Miriam Braeuer, Yuanfang Li, Negar Omidvari, Geoffrey Topping, Ting Sun, Stephan G. Nekolla, Antonia Richter, Christian Weber, Andreas Habenicht, Uwe A. Haberkorn and Wolfgang A. Weber
Journal of Nuclear Medicine December 2019, 60 (12) 1743-1749; DOI: https://doi.org/10.2967/jnumed.119.226993
Zohreh Varasteh
1Department of Nuclear Medicine, Klinikum rechts der Isar der TUM, Munich, Germany
Sarajo Mohanta
2Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität, Munich, Germany
3German Centre for Cardiovascular Research, Munich Heart Alliance, Munich, Germany; and
Stephanie Robu
1Department of Nuclear Medicine, Klinikum rechts der Isar der TUM, Munich, Germany
Miriam Braeuer
1Department of Nuclear Medicine, Klinikum rechts der Isar der TUM, Munich, Germany
Yuanfang Li
2Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität, Munich, Germany
Negar Omidvari
1Department of Nuclear Medicine, Klinikum rechts der Isar der TUM, Munich, Germany
Geoffrey Topping
1Department of Nuclear Medicine, Klinikum rechts der Isar der TUM, Munich, Germany
Ting Sun
2Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität, Munich, Germany
Stephan G. Nekolla
1Department of Nuclear Medicine, Klinikum rechts der Isar der TUM, Munich, Germany
Antonia Richter
1Department of Nuclear Medicine, Klinikum rechts der Isar der TUM, Munich, Germany
Christian Weber
2Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität, Munich, Germany
3German Centre for Cardiovascular Research, Munich Heart Alliance, Munich, Germany; and
Andreas Habenicht
2Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität, Munich, Germany
Uwe A. Haberkorn
4Department of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany
Wolfgang A. Weber
1Department of Nuclear Medicine, Klinikum rechts der Isar der TUM, Munich, Germany

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 60, Issue 12
December 1, 2019
Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04
Zohreh Varasteh, Sarajo Mohanta, Stephanie Robu, Miriam Braeuer, Yuanfang Li, Negar Omidvari, Geoffrey Topping, Ting Sun, Stephan G. Nekolla, Antonia Richter, Christian Weber, Andreas Habenicht, Uwe A. Haberkorn, Wolfgang A. Weber
Journal of Nuclear Medicine Dec 2019, 60 (12) 1743-1749; DOI: 10.2967/jnumed.119.226993
Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04
Zohreh Varasteh, Sarajo Mohanta, Stephanie Robu, Miriam Braeuer, Yuanfang Li, Negar Omidvari, Geoffrey Topping, Ting Sun, Stephan G. Nekolla, Antonia Richter, Christian Weber, Andreas Habenicht, Uwe A. Haberkorn, Wolfgang A. Weber
Journal of Nuclear Medicine Dec 2019, 60 (12) 1743-1749; DOI: 10.2967/jnumed.119.226993
Jump to section
Related Articles
Cited By...
- Combination of Forced Diuresis with Additional Late Imaging in 68Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake
- The Latest Developments in Imaging of Fibroblast Activation Protein
- FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
- Targeted PET Imaging of Chemokine Receptor 2-Positive Monocytes and Macrophages in the Injured Heart
- Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy
- The Future of Nuclear Medicine Depends on the Quality of Its Research: Researchers at the University of Heidelberg Receive the Award for Best Article of the Year
- The Changing Face of Nuclear Cardiology: Guiding Cardiovascular Care Toward Molecular Medicine
- CARTing Away Cardiac Fibrosis
- FAP: The Next Billion Dollar Nuclear Theranostics Target?